ストックスクリーナーアプリを入手
0.6897
5.13%
-0.0373
アフターアワーズ：
.67
-0.0197
-2.86%
前日終値:
$0.727
開ける：
$0.7135
24時間の取引高:
1.21M
Relative Volume:
0.38
時価総額：
$270.76M
収益：
$86.26M
当期純損益:
$-50.08M
株価収益率:
-2.8163
EPS:
-0.2449
ネットキャッシュフロー:
$-94.48M
1週間 パフォーマンス:
+2.34%
1か月 パフォーマンス:
-12.56%
6か月 パフォーマンス:
-30.33%
1年 パフォーマンス:
-46.12%
1日の値動き範囲:
$0.675
$0.7174
1週間の範囲:
$0.6628
$0.7342
52週間の値動き範囲:
$0.6251
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Compare LAB vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.6897 | 285.40M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-27 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | 開始されました | TD Cowen | Buy |
| 2024-04-04 | 開始されました | Jefferies | Buy |
| 2023-07-12 | 開始されました | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc (LAB) 最新ニュース
Treeline deal leaves Standard BioTools (NASDAQ: LAB) investors with a minority stake - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—IRDM, VRME, VAL and LAB - GlobeNewswire Inc.
Standard BioTools And 2 Other Promising Penny Stocks For Your Watchlist - simplywall.st
Standard BioTools (LAB) Slips 1.24% to $0.65 as Tight Trading Range Takes ShapeBPI Bear Correction - dars.gov.et
Standard Biotools Inc (LAB) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Standard BioTools (LAB) CEO uses 97K shares to pay taxes - Stock Titan
Standard (LAB) Session: Moves 0.73% Up to $0.65; Next Session: the Near-Term Reference Band Stretches From $0.62 to $0.68 under the Current SnapshotSentiment Shift - vinanet.vn
Enterprise value to EBIT forward of Standard BioTools Inc. – BX:FLB - TradingView
Long Focus Capital Management, LLC Adds to Standard BioTools Inc - GuruFocus
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Standard BioTools (LAB) Slides 4.99% to $0.71 as Selling Pressure PersistsFactor Valuation - vinanet.vn
Standard BioTools Inc (LAB) Fundamental & Financial Data - Stocktwits
Standard BioTools (LAB) holders report 7.3% stake in amended ownership filing - Stock Titan
Standard BioTools Inc.: Target Price Consensus and Analysts Recommendations | LAB | US34385P1084 - marketscreener.com
Standard BioTools Inc (LAB) sentiment score, message volume, participation score and buzz level - Stocktwits
LAB: Standard BioTools Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Standard BioTools (LAB): Long Focus Capital discloses 23.5M shares, 6% passive stake - Stock Titan
Standard BioTools (LAB) Short Interest & Short Float | Updated Aug 2026 $LAB - MarketBeat
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Standard BioTools Inc (LAB) Stock News Today - TradingKey
Is Standard BioTools Inc (LAB) Overvalued After Q2 Loss? EPS: -$0.21, Revenue: $20.1M -- GF Score: 33/100 - GuruFocus
Standard BioTools Inc. (LAB) Stock Report: Evaluating a Potential 93% Upside in the Medical Devices Sector - DirectorsTalk Interviews
Standard BioTools (LAB) Holds Steady at $0.80: Consolidation or Pivot Point Ahead?Growth Stock Picks - dars.gov.et
Standard BioTools Reports Second Quarter 2026 Financial Results - The Manila Times
BlackRock, Inc. Reduces Standard BioTools Inc (LAB) Stake -- Sha - GuruFocus
Standard BioTools Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Standard BioTools (NASDAQ:LAB) Issues Earnings Results - MarketBeat
Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss - TradingKey
Standard BioTools Q2 revenue falls on consumables weakness - TradingView
STANDARD BIOTOOLS ($LAB) Releases Q2 2026 Earnings - Quiver Quantitative
STANDARD BIOTOOLS INC. Q2 2026: Revenue $20.1M, EPS $(0.07) — 10-Q Summary - TradingView
Standard BioTools: Q2 Earnings Snapshot - barchart.com
Standard BioTools (NASDAQ: LAB) Q2 revenue $20.1M as merger advances - Stock Titan
Standard BioTools Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BRIEF-Standard BioTools Q2 EPS USD -0.07 - TradingView
Standard Biotools Inc. Withdraws Earnings Guidance for the Full Year 2026 - marketscreener.com
Price to sales forward of Standard BioTools Inc. – BX:FLB - TradingView
Aug 05 (Reuters)Standard BioTools Q2 Reven - Moomoo
Standard BioTools (LAB) CEO has 362,625 shares withheld for taxes - stocktitan.net
Standard BioTools Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Standard BioTools Inc. expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Standard BioTools Inc. (NASDAQ:LAB) Short Interest Update - MarketBeat
BlackRock (LAB) reports 7.9M-share, 2.0% position in Standard BioTools - Stock Titan
Standard BioTools Updates Disclosure on Mass Cytometry Business Sale to Multiplex Bio Amid Strategic Portfolio Restructuring - Kalkine Media
Form 4 Standard Biotools Inc For: 28 July By Investing.com - Investing.com Nigeria
Standard BioTools sells mass cytometry unit, gets $30M buyout By Investing.com - Investing.com Nigeria
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences - Moomoo
- SEC.gov
Standard BioTools (LAB) plans sale of Mass Cytometry business alongside Treeline deal - Stock Titan
Standard BioTools sells mass cytometry unit, gets $30M buyout - Investing.com
Standard BioTools Sells Mass Cytometry Business and Secures $30 Million Illumina Buyout Ahead of Treeline Merger - citybiz
Standard Biotools Inc (LAB) 財務データ
収益
当期純利益
現金流量
EPS
2.29%
0.75%
大文字化:
|
ボリューム (24 時間):